Recall: D-0541-2026

Class II - Potentially Harmful

Class IIClassification

2026-04-24Initiated

OngoingStatus

Lupin Pharmaceuticals Inc.Firm

Product

Liraglutide Injection, 18 mg/3 mL (6 mg/mL), Rx only, Manufactured for: Lupin Pharmaceuticals, Inc., Naples, FL 34108, Manufactured by: Lupin Limited, Nagpur 441108, INDIA, a) 2 Pens- NDC 70748-346-02; b) 3 Pens - NDC 70748-346-03.

Reason

Presence of particulate matter: a white thread-like structure in the cartridge

Distribution

Nationwide within U.S

Source: FDA drug enforcement report via openFDA (Voluntary: Firm initiated). If you take this product, talk to your pharmacist or doctor before stopping it.